Share Price and Basic Stock Data
Last Updated: January 14, 2026, 9:20 pm
| PEG Ratio | 1.93 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Marksans Pharma Ltd operates within the pharmaceuticals industry, showcasing a robust revenue growth trajectory. The company reported sales of ₹1,852 Cr for the fiscal year ending March 2023, which rose to ₹2,177 Cr in March 2024, marking an increase of 17.5%. For the trailing twelve months (TTM), sales stood at ₹2,731 Cr, reflecting a consistent upward trend in revenue generation. Quarterly sales figures further illustrate this growth, with revenue increasing from ₹453 Cr in September 2022 to ₹531 Cr in September 2023, and projected to reach ₹642 Cr by September 2024. This growth is supported by an operating profit margin (OPM) of 20% and an operating profit of ₹340 Cr for FY 2023, indicating effective cost management alongside revenue expansion. The company’s focus on enhancing its product portfolio and entering new markets is pivotal in sustaining this upward trajectory, positioning Marksans Pharma as a competitive player in the pharmaceutical sector.
Profitability and Efficiency Metrics
Marksans Pharma has demonstrated solid profitability metrics, evidenced by a net profit of ₹353 Cr and a return on equity (ROE) of 16.8% for the latest reporting period. The operating profit margin (OPM) has remained stable, recorded at 20% for FY 2025, and the net profit margin stood at 14.58%, indicating effective management of expenses relative to sales. The company’s interest coverage ratio (ICR) is notably high at 51.37x, suggesting strong earnings relative to interest obligations, thereby reducing financial risk. Additionally, the cash conversion cycle (CCC) of 247 days reflects efficient management of working capital, although it is on the higher side compared to typical industry standards. The company has also maintained a consistent dividend payout ratio, which rose to 10% for FY 2025, indicating a commitment to returning value to shareholders while retaining sufficient earnings for reinvestment.
Balance Sheet Strength and Financial Ratios
The balance sheet of Marksans Pharma illustrates a strong financial position, with total assets amounting to ₹3,240 Cr and total liabilities at ₹3,442 Cr as of March 2025. The company’s reserves have increased significantly, reaching ₹2,643 Cr, which bolsters its equity base and provides a cushion for future investments. With borrowings of only ₹332 Cr, Marksans maintains a low debt-to-equity ratio of 0.01, indicating minimal reliance on external debt to finance operations. The current ratio is robust at 4.62, suggesting ample liquidity to cover short-term obligations. Furthermore, the price-to-book value (P/BV) ratio stands at 4.08x, which, while higher than typical sector ranges, signifies market confidence in the company’s growth prospects. These factors collectively indicate a well-capitalized firm poised for sustained operational and financial stability.
Shareholding Pattern and Investor Confidence
The shareholding structure of Marksans Pharma reflects a balanced distribution among promoters, foreign institutional investors (FIIs), domestic institutional investors (DIIs), and the public. Promoters hold a significant 43.87% stake, which has remained stable over the past quarters, indicating their confidence in the company’s future. FIIs have increased their stake from 4.23% in December 2022 to 16.92% as of September 2025, showcasing growing investor interest in the firm. DIIs also hold 5.28%, suggesting institutional support, while the public holds 33.93%. The total number of shareholders has increased to 2,65,788, reflecting enhanced retail participation. This diverse ownership structure promotes stability and confidence among investors, although a high concentration of ownership can pose risks during market volatility, potentially impacting share price stability.
Outlook, Risks, and Final Insight
Looking ahead, Marksans Pharma is well-positioned for continued growth, driven by its expanding product portfolio and strategic market initiatives. However, risks remain, including potential regulatory challenges and competitive pressures within the pharmaceutical sector. The company’s reliance on a stable supply chain and cost management practices will be crucial in navigating these challenges. Furthermore, fluctuations in raw material prices could impact profit margins. Should the company successfully leverage its operational strengths and manage these risks effectively, it may enhance shareholder value and sustain its growth trajectory. The commitment to innovation and quality in product offerings will be pivotal in maintaining competitive advantages in an evolving market landscape. Overall, Marksans Pharma’s solid financial foundation and proactive management strategies provide a favorable outlook for its future performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 130 Cr. | 103 | 208/84.3 | 28.7 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,065 Cr. | 373 | 479/192 | 84.2 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.4 Cr. | 45.0 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.6 Cr. | 40.0 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,199.61 Cr | 1,121.95 | 52.58 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 453 | 480 | 486 | 500 | 531 | 586 | 560 | 591 | 642 | 682 | 708 | 620 | 720 |
| Expenses | 372 | 403 | 376 | 398 | 417 | 453 | 450 | 462 | 495 | 543 | 582 | 520 | 576 |
| Operating Profit | 80 | 77 | 110 | 102 | 114 | 133 | 110 | 128 | 147 | 139 | 127 | 100 | 144 |
| OPM % | 18% | 16% | 23% | 20% | 21% | 23% | 20% | 22% | 23% | 20% | 18% | 16% | 20% |
| Other Income | 14 | 18 | 11 | 10 | 19 | 5 | 17 | 15 | -0 | 28 | 15 | 6 | 22 |
| Interest | 3 | 2 | 2 | 2 | 2 | 3 | 5 | 3 | 3 | 3 | 3 | 6 | 6 |
| Depreciation | 14 | 13 | 14 | 14 | 18 | 22 | 21 | 20 | 20 | 21 | 23 | 23 | 27 |
| Profit before tax | 78 | 79 | 104 | 97 | 114 | 113 | 100 | 120 | 125 | 143 | 116 | 77 | 133 |
| Tax % | 23% | 21% | 21% | 27% | 26% | 26% | 23% | 26% | 22% | 27% | 22% | 24% | 26% |
| Net Profit | 60 | 62 | 83 | 70 | 84 | 83 | 78 | 89 | 98 | 105 | 91 | 58 | 99 |
| EPS in Rs | 1.51 | 1.57 | 1.81 | 1.52 | 1.84 | 1.84 | 1.73 | 1.96 | 2.13 | 2.31 | 2.00 | 1.29 | 2.17 |
Last Updated: December 30, 2025, 1:06 am
Below is a detailed analysis of the quarterly data for Marksans Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 720.00 Cr.. The value appears strong and on an upward trend. It has increased from 620.00 Cr. (Jun 2025) to 720.00 Cr., marking an increase of 100.00 Cr..
- For Expenses, as of Sep 2025, the value is 576.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 520.00 Cr. (Jun 2025) to 576.00 Cr., marking an increase of 56.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 144.00 Cr.. The value appears strong and on an upward trend. It has increased from 100.00 Cr. (Jun 2025) to 144.00 Cr., marking an increase of 44.00 Cr..
- For OPM %, as of Sep 2025, the value is 20.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Jun 2025) to 20.00%, marking an increase of 4.00%.
- For Other Income, as of Sep 2025, the value is 22.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Jun 2025) to 22.00 Cr., marking an increase of 16.00 Cr..
- For Interest, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 6.00 Cr..
- For Depreciation, as of Sep 2025, the value is 27.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 23.00 Cr. (Jun 2025) to 27.00 Cr., marking an increase of 4.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 133.00 Cr.. The value appears strong and on an upward trend. It has increased from 77.00 Cr. (Jun 2025) to 133.00 Cr., marking an increase of 56.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Jun 2025) to 26.00%, marking an increase of 2.00%.
- For Net Profit, as of Sep 2025, the value is 99.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Jun 2025) to 99.00 Cr., marking an increase of 41.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.17. The value appears strong and on an upward trend. It has increased from 1.29 (Jun 2025) to 2.17, marking an increase of 0.88.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:00 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 630 | 797 | 893 | 767 | 913 | 1,000 | 1,134 | 1,376 | 1,491 | 1,852 | 2,177 | 2,623 | 2,731 |
| Expenses | 512 | 612 | 757 | 722 | 834 | 868 | 942 | 1,037 | 1,232 | 1,513 | 1,719 | 2,094 | 2,220 |
| Operating Profit | 118 | 185 | 136 | 45 | 78 | 132 | 192 | 340 | 259 | 340 | 459 | 529 | 510 |
| OPM % | 19% | 23% | 15% | 6% | 9% | 13% | 17% | 25% | 17% | 18% | 21% | 20% | 19% |
| Other Income | 4 | 3 | 9 | 7 | 8 | 5 | 0 | 7 | 42 | 59 | 50 | 70 | 70 |
| Interest | 19 | 16 | 10 | 7 | 10 | 10 | 9 | 8 | 8 | 9 | 11 | 12 | 18 |
| Depreciation | 16 | 16 | 28 | 30 | 27 | 23 | 27 | 36 | 45 | 52 | 74 | 83 | 93 |
| Profit before tax | 86 | 156 | 107 | 15 | 50 | 104 | 157 | 302 | 248 | 338 | 424 | 504 | 469 |
| Tax % | 15% | 28% | 23% | 24% | 28% | 23% | 23% | 21% | 25% | 21% | 26% | 24% | |
| Net Profit | 74 | 112 | 83 | 11 | 36 | 80 | 121 | 239 | 187 | 265 | 315 | 383 | 353 |
| EPS in Rs | 1.87 | 2.67 | 1.92 | 0.22 | 0.80 | 1.87 | 2.95 | 5.76 | 4.51 | 5.88 | 6.92 | 8.40 | 7.77 |
| Dividend Payout % | 5% | 4% | 21% | 23% | 6% | 3% | 3% | 4% | 6% | 9% | 9% | 10% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 51.35% | -25.89% | -86.75% | 227.27% | 122.22% | 51.25% | 97.52% | -21.76% | 41.71% | 18.87% | 21.59% |
| Change in YoY Net Profit Growth (%) | 0.00% | -77.24% | -60.85% | 314.02% | -105.05% | -70.97% | 46.27% | -119.28% | 63.47% | -22.84% | 2.72% |
Marksans Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 18% |
| 3 Years: | 21% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 26% |
| 3 Years: | 27% |
| TTM: | 5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 30% |
| 3 Years: | 48% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 19% |
| 3 Years: | 17% |
| Last Year: | 17% |
Last Updated: Unknown
Balance Sheet
Last Updated: December 4, 2025, 1:37 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 39 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 45 | 45 | 45 | 45 |
| Reserves | 90 | 326 | 401 | 392 | 430 | 502 | 595 | 846 | 1,161 | 1,700 | 2,020 | 2,422 | 2,643 |
| Borrowings | 173 | 101 | 100 | 110 | 118 | 100 | 30 | 34 | 111 | 123 | 244 | 322 | 332 |
| Other Liabilities | 188 | 207 | 180 | 209 | 142 | 160 | 236 | 307 | 323 | 322 | 372 | 451 | 422 |
| Total Liabilities | 490 | 676 | 722 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 2,190 | 2,681 | 3,240 | 3,442 |
| Fixed Assets | 146 | 166 | 270 | 267 | 279 | 270 | 303 | 309 | 428 | 486 | 776 | 982 | 1,054 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 3 | 10 | 9 | 27 | 7 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 27 | 1 | 1 |
| Other Assets | 344 | 510 | 452 | 484 | 451 | 533 | 599 | 907 | 1,205 | 1,694 | 1,869 | 2,230 | 2,381 |
| Total Assets | 490 | 676 | 722 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 2,190 | 2,681 | 3,240 | 3,442 |
Below is a detailed analysis of the balance sheet data for Marksans Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 45.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,643.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,422.00 Cr. (Mar 2025) to 2,643.00 Cr., marking an increase of 221.00 Cr..
- For Borrowings, as of Sep 2025, the value is 332.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 322.00 Cr. (Mar 2025) to 332.00 Cr., marking an increase of 10.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 422.00 Cr.. The value appears to be improving (decreasing). It has decreased from 451.00 Cr. (Mar 2025) to 422.00 Cr., marking a decrease of 29.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,442.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,240.00 Cr. (Mar 2025) to 3,442.00 Cr., marking an increase of 202.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,054.00 Cr.. The value appears strong and on an upward trend. It has increased from 982.00 Cr. (Mar 2025) to 1,054.00 Cr., marking an increase of 72.00 Cr..
- For CWIP, as of Sep 2025, the value is 7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 27.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 20.00 Cr..
- For Investments, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,381.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,230.00 Cr. (Mar 2025) to 2,381.00 Cr., marking an increase of 151.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,442.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,240.00 Cr. (Mar 2025) to 3,442.00 Cr., marking an increase of 202.00 Cr..
Notably, the Reserves (2,643.00 Cr.) exceed the Borrowings (332.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -55.00 | 84.00 | 36.00 | -65.00 | -40.00 | 32.00 | 162.00 | 306.00 | 148.00 | 217.00 | 215.00 | 207.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 98 | 84 | 89 | 118 | 71 | 64 | 78 | 72 | 97 | 82 | 76 | 75 |
| Inventory Days | 102 | 107 | 120 | 151 | 152 | 215 | 155 | 248 | 216 | 192 | 217 | 270 |
| Days Payable | 83 | 88 | 85 | 129 | 54 | 78 | 71 | 103 | 102 | 91 | 94 | 98 |
| Cash Conversion Cycle | 118 | 103 | 124 | 140 | 169 | 202 | 163 | 217 | 211 | 183 | 199 | 247 |
| Working Capital Days | -13 | 17 | 59 | 77 | 70 | 97 | 87 | 104 | 121 | 122 | 129 | 142 |
| ROCE % | 37% | 44% | 23% | 4% | 10% | 18% | 25% | 38% | 23% | 22% | 21% | 20% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Bandhan Small Cap Fund | 3,335,509 | 0.34 | 62.69 | N/A | N/A | N/A |
| UTI Small Cap Fund | 2,794,081 | 1.09 | 52.51 | 2,518,039 | 2025-12-15 01:41:26 | 10.96% |
| UTI Aggressive Hybrid Fund | 2,159,816 | 0.6 | 40.59 | 2,078,253 | 2025-12-08 01:26:44 | 3.92% |
| UTI Large & Mid Cap Fund | 2,019,995 | 0.69 | 37.97 | 1,082,611 | 2025-12-08 01:26:44 | 86.59% |
| UTI Healthcare Fund | 755,000 | 1.26 | 14.19 | 232,711 | 2025-12-08 01:26:44 | 224.44% |
| UTI Retirement Fund | 701,714 | 0.28 | 13.19 | 1,049,499 | 2025-12-08 01:26:44 | -33.14% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 8.40 | 6.92 | 6.41 | 4.51 | 5.76 |
| Diluted EPS (Rs.) | 8.40 | 6.92 | 6.41 | 4.51 | 5.76 |
| Cash EPS (Rs.) | 10.28 | 8.59 | 7.00 | 5.66 | 6.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 54.44 | 46.03 | 38.95 | 29.88 | 22.12 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 54.44 | 46.03 | 38.95 | 29.88 | 22.12 |
| Revenue From Operations / Share (Rs.) | 57.88 | 48.05 | 40.87 | 36.42 | 33.62 |
| PBDIT / Share (Rs.) | 13.22 | 11.23 | 8.80 | 7.35 | 8.46 |
| PBIT / Share (Rs.) | 11.38 | 9.59 | 7.65 | 6.25 | 7.58 |
| PBT / Share (Rs.) | 11.12 | 9.35 | 7.45 | 6.05 | 7.38 |
| Net Profit / Share (Rs.) | 8.44 | 6.95 | 5.85 | 4.56 | 5.83 |
| NP After MI And SOA / Share (Rs.) | 8.40 | 6.92 | 5.88 | 4.56 | 5.83 |
| PBDIT Margin (%) | 22.83 | 23.37 | 21.52 | 20.17 | 25.16 |
| PBIT Margin (%) | 19.65 | 19.96 | 18.72 | 17.16 | 22.53 |
| PBT Margin (%) | 19.21 | 19.45 | 18.23 | 16.60 | 21.95 |
| Net Profit Margin (%) | 14.58 | 14.46 | 14.32 | 12.53 | 17.33 |
| NP After MI And SOA Margin (%) | 14.51 | 14.40 | 14.37 | 12.53 | 17.33 |
| Return on Networth / Equity (%) | 15.42 | 15.19 | 15.25 | 15.53 | 26.90 |
| Return on Capital Employeed (%) | 18.66 | 18.97 | 18.75 | 19.93 | 33.35 |
| Return On Assets (%) | 11.74 | 11.70 | 12.15 | 11.39 | 19.42 |
| Total Debt / Equity (X) | 0.01 | 0.01 | 0.02 | 0.03 | 0.02 |
| Asset Turnover Ratio (%) | 0.88 | 0.89 | 0.96 | 1.04 | 0.73 |
| Current Ratio (X) | 4.62 | 4.78 | 4.91 | 3.37 | 3.02 |
| Quick Ratio (X) | 2.85 | 3.19 | 3.49 | 2.18 | 1.67 |
| Inventory Turnover Ratio (X) | 3.58 | 1.21 | 1.35 | 1.30 | 1.74 |
| Dividend Payout Ratio (NP) (%) | 7.14 | 7.22 | 3.81 | 5.47 | 1.71 |
| Dividend Payout Ratio (CP) (%) | 5.86 | 5.84 | 3.19 | 4.41 | 1.49 |
| Earning Retention Ratio (%) | 92.86 | 92.78 | 96.19 | 94.53 | 98.29 |
| Cash Earning Retention Ratio (%) | 94.14 | 94.16 | 96.81 | 95.59 | 98.51 |
| Interest Coverage Ratio (X) | 51.37 | 45.43 | 43.67 | 35.61 | 43.36 |
| Interest Coverage Ratio (Post Tax) (X) | 33.81 | 29.11 | 30.07 | 23.12 | 30.87 |
| Enterprise Value (Cr.) | 9417.36 | 6244.01 | 2540.86 | 1577.14 | 1869.83 |
| EV / Net Operating Revenue (X) | 3.59 | 2.87 | 1.37 | 1.06 | 1.36 |
| EV / EBITDA (X) | 15.72 | 12.27 | 6.37 | 5.24 | 5.40 |
| MarketCap / Net Operating Revenue (X) | 3.84 | 3.15 | 1.72 | 1.25 | 1.49 |
| Retention Ratios (%) | 92.85 | 92.77 | 96.18 | 94.52 | 98.28 |
| Price / BV (X) | 4.08 | 3.33 | 1.83 | 1.55 | 2.31 |
| Price / Net Operating Revenue (X) | 3.84 | 3.15 | 1.72 | 1.25 | 1.49 |
| EarningsYield | 0.03 | 0.04 | 0.08 | 0.10 | 0.11 |
After reviewing the key financial ratios for Marksans Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.40. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 8.40, marking an increase of 1.48.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.40. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 8.40, marking an increase of 1.48.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.28. This value is within the healthy range. It has increased from 8.59 (Mar 24) to 10.28, marking an increase of 1.69.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 54.44. It has increased from 46.03 (Mar 24) to 54.44, marking an increase of 8.41.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 54.44. It has increased from 46.03 (Mar 24) to 54.44, marking an increase of 8.41.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 57.88. It has increased from 48.05 (Mar 24) to 57.88, marking an increase of 9.83.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.22. This value is within the healthy range. It has increased from 11.23 (Mar 24) to 13.22, marking an increase of 1.99.
- For PBIT / Share (Rs.), as of Mar 25, the value is 11.38. This value is within the healthy range. It has increased from 9.59 (Mar 24) to 11.38, marking an increase of 1.79.
- For PBT / Share (Rs.), as of Mar 25, the value is 11.12. This value is within the healthy range. It has increased from 9.35 (Mar 24) to 11.12, marking an increase of 1.77.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 8.44. This value is within the healthy range. It has increased from 6.95 (Mar 24) to 8.44, marking an increase of 1.49.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.40. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 8.40, marking an increase of 1.48.
- For PBDIT Margin (%), as of Mar 25, the value is 22.83. This value is within the healthy range. It has decreased from 23.37 (Mar 24) to 22.83, marking a decrease of 0.54.
- For PBIT Margin (%), as of Mar 25, the value is 19.65. This value is within the healthy range. It has decreased from 19.96 (Mar 24) to 19.65, marking a decrease of 0.31.
- For PBT Margin (%), as of Mar 25, the value is 19.21. This value is within the healthy range. It has decreased from 19.45 (Mar 24) to 19.21, marking a decrease of 0.24.
- For Net Profit Margin (%), as of Mar 25, the value is 14.58. This value exceeds the healthy maximum of 10. It has increased from 14.46 (Mar 24) to 14.58, marking an increase of 0.12.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 14.51. This value is within the healthy range. It has increased from 14.40 (Mar 24) to 14.51, marking an increase of 0.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.42. This value is within the healthy range. It has increased from 15.19 (Mar 24) to 15.42, marking an increase of 0.23.
- For Return on Capital Employeed (%), as of Mar 25, the value is 18.66. This value is within the healthy range. It has decreased from 18.97 (Mar 24) to 18.66, marking a decrease of 0.31.
- For Return On Assets (%), as of Mar 25, the value is 11.74. This value is within the healthy range. It has increased from 11.70 (Mar 24) to 11.74, marking an increase of 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.88. It has decreased from 0.89 (Mar 24) to 0.88, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 4.62. This value exceeds the healthy maximum of 3. It has decreased from 4.78 (Mar 24) to 4.62, marking a decrease of 0.16.
- For Quick Ratio (X), as of Mar 25, the value is 2.85. This value exceeds the healthy maximum of 2. It has decreased from 3.19 (Mar 24) to 2.85, marking a decrease of 0.34.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.58. This value is below the healthy minimum of 4. It has increased from 1.21 (Mar 24) to 3.58, marking an increase of 2.37.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 7.14. This value is below the healthy minimum of 20. It has decreased from 7.22 (Mar 24) to 7.14, marking a decrease of 0.08.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.86. This value is below the healthy minimum of 20. It has increased from 5.84 (Mar 24) to 5.86, marking an increase of 0.02.
- For Earning Retention Ratio (%), as of Mar 25, the value is 92.86. This value exceeds the healthy maximum of 70. It has increased from 92.78 (Mar 24) to 92.86, marking an increase of 0.08.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.14. This value exceeds the healthy maximum of 70. It has decreased from 94.16 (Mar 24) to 94.14, marking a decrease of 0.02.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 51.37. This value is within the healthy range. It has increased from 45.43 (Mar 24) to 51.37, marking an increase of 5.94.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 33.81. This value is within the healthy range. It has increased from 29.11 (Mar 24) to 33.81, marking an increase of 4.70.
- For Enterprise Value (Cr.), as of Mar 25, the value is 9,417.36. It has increased from 6,244.01 (Mar 24) to 9,417.36, marking an increase of 3,173.35.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.59. This value exceeds the healthy maximum of 3. It has increased from 2.87 (Mar 24) to 3.59, marking an increase of 0.72.
- For EV / EBITDA (X), as of Mar 25, the value is 15.72. This value exceeds the healthy maximum of 15. It has increased from 12.27 (Mar 24) to 15.72, marking an increase of 3.45.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.84. This value exceeds the healthy maximum of 3. It has increased from 3.15 (Mar 24) to 3.84, marking an increase of 0.69.
- For Retention Ratios (%), as of Mar 25, the value is 92.85. This value exceeds the healthy maximum of 70. It has increased from 92.77 (Mar 24) to 92.85, marking an increase of 0.08.
- For Price / BV (X), as of Mar 25, the value is 4.08. This value exceeds the healthy maximum of 3. It has increased from 3.33 (Mar 24) to 4.08, marking an increase of 0.75.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.84. This value exceeds the healthy maximum of 3. It has increased from 3.15 (Mar 24) to 3.84, marking an increase of 0.69.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Marksans Pharma Ltd:
- Net Profit Margin: 14.58%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.66% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.42% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 33.81
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.85
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 22.2 (Industry average Stock P/E: 52.58)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 14.58%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 11th Floor, Grandeur, Veera Desai Extension Road, Mumbai Maharashtra 400053 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mark Saldanha | Chairman & Managing Director |
| Mrs. Sandra Saldanha | Whole Time Director |
| Mr. Varddhman V Jain | Whole Time Director |
| Dr. Sunny Sharma | Non Executive Director |
| Mr. Srinivas Mishra | Independent Director |
| Mr. Digant Mahesh Parikh | Independent Director |
| Mr. Abhinna Sundar Mohanty | Independent Director |
| Mrs. Shailaja Vardhan | Independent Director |
FAQ
What is the intrinsic value of Marksans Pharma Ltd?
Marksans Pharma Ltd's intrinsic value (as of 14 January 2026) is ₹177.75 which is 3.34% higher the current market price of ₹172.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹7,824 Cr. market cap, FY2025-2026 high/low of ₹276/162, reserves of ₹2,643 Cr, and liabilities of ₹3,442 Cr.
What is the Market Cap of Marksans Pharma Ltd?
The Market Cap of Marksans Pharma Ltd is 7,824 Cr..
What is the current Stock Price of Marksans Pharma Ltd as on 14 January 2026?
The current stock price of Marksans Pharma Ltd as on 14 January 2026 is ₹172.
What is the High / Low of Marksans Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Marksans Pharma Ltd stocks is ₹276/162.
What is the Stock P/E of Marksans Pharma Ltd?
The Stock P/E of Marksans Pharma Ltd is 22.2.
What is the Book Value of Marksans Pharma Ltd?
The Book Value of Marksans Pharma Ltd is 59.3.
What is the Dividend Yield of Marksans Pharma Ltd?
The Dividend Yield of Marksans Pharma Ltd is 0.46 %.
What is the ROCE of Marksans Pharma Ltd?
The ROCE of Marksans Pharma Ltd is 20.0 %.
What is the ROE of Marksans Pharma Ltd?
The ROE of Marksans Pharma Ltd is 16.8 %.
What is the Face Value of Marksans Pharma Ltd?
The Face Value of Marksans Pharma Ltd is 1.00.